These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 32213029)

  • 1. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
    Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
    United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PDX-derived organoids model in vivo drug response and secrete biomarkers.
    Huang L; Bockorny B; Paul I; Akshinthala D; Frappart PO; Gandarilla O; Bose A; Sanchez-Gonzalez V; Rouse EE; Lehoux SD; Pandell N; Lim CM; Clohessy JG; Grossman J; Gonzalez R; Del Pino SP; Daaboul G; Sawhney MS; Freedman SD; Kleger A; Cummings RD; Emili A; Muthuswamy LB; Hidalgo M; Muthuswamy SK
    JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
    Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
    EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
    Huang L; Holtzinger A; Jagan I; BeGora M; Lohse I; Ngai N; Nostro C; Wang R; Muthuswamy LB; Crawford HC; Arrowsmith C; Kalloger SE; Renouf DJ; Connor AA; Cleary S; Schaeffer DF; Roehrl M; Tsao MS; Gallinger S; Keller G; Muthuswamy SK
    Nat Med; 2015 Nov; 21(11):1364-71. PubMed ID: 26501191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
    Pham NA; Radulovich N; Ibrahimov E; Martins-Filho SN; Li Q; Pintilie M; Weiss J; Raghavan V; Cabanero M; Denroche RE; Wilson JM; Metran-Nascente C; Borgida A; Hutchinson S; Dodd A; Begora M; Chadwick D; Serra S; Knox JJ; Gallinger S; Hedley DW; Muthuswamy L; Tsao MS
    Sci Rep; 2021 May; 11(1):10619. PubMed ID: 34011980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites.
    Allaway RJ; Fischer DA; de Abreu FB; Gardner TB; Gordon SR; Barth RJ; Colacchio TA; Wood M; Kacsoh BZ; Bouley SJ; Cui J; Hamilton J; Choi JA; Lange JT; Peterson JD; Padmanabhan V; Tomlinson CR; Tsongalis GJ; Suriawinata AA; Greene CS; Sanchez Y; Smith KD
    Oncotarget; 2016 Mar; 7(13):17087-102. PubMed ID: 26934555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems.
    Solanki A; King D; Thibault G; Wang L; Gibbs SL
    PLoS One; 2020; 15(2):e0229407. PubMed ID: 32097436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
    Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
    Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The establishment of kidney cancer organoid line in drug testing.
    Tse RT; Wong CY; Ding X; Cheng CK; Chow C; Chan RC; Ng JH; Tang VW; Chiu PK; Teoh JY; Wong N; To KF; Ng CF
    Cancer Med; 2024 Jun; 13(12):e7432. PubMed ID: 38923304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a Single-Cell Technique to Increase Yield and Use of Gastrointestinal Cancer Organoids for Personalized Medicine Application.
    Gao M; Harper MM; Lin M; Qasem SA; Patel RA; Mardini SH; Gabr MM; Cavnar MJ; Pandalai PK; Kim J
    J Am Coll Surg; 2021 Apr; 232(4):504-514. PubMed ID: 33253861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.
    Matsumoto K; Fujimori N; Ichihara K; Takeno A; Murakami M; Ohno A; Kakehashi S; Teramatsu K; Ueda K; Nakata K; Sugahara O; Yamamoto T; Matsumoto A; Nakayama KI; Oda Y; Nakamura M; Ogawa Y
    J Gastroenterol; 2024 Jul; 59(7):629-640. PubMed ID: 38684511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
    Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
    Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
    Zhang Y; Houchen CW; Li M
    Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and Culture of Human Pancreatic Ductal Adenocarcinoma Organoids from Resected Tumor Specimens.
    Baker LA; Tiriac H; Tuveson DA
    Methods Mol Biol; 2019; 1882():97-115. PubMed ID: 30378047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoids for Functional Precision Medicine in Advanced Pancreatic Cancer.
    Boilève A; Cartry J; Goudarzi N; Bedja S; Mathieu JRR; Bani MA; Nicolle R; Mouawia A; Bouyakoub R; Nicotra C; Ngo-Camus M; Job B; Lipson K; Boige V; Valéry M; Tarabay A; Dartigues P; Tselikas L; de Baere T; Italiano A; Cosconea S; Gelli M; Fernandez-de-Sevilla E; Annereau M; Malka D; Smolenschi C; Ducreux M; Hollebecque A; Jaulin F
    Gastroenterology; 2024 Oct; 167(5):961-976.e13. PubMed ID: 38866343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.
    Sandhya S; Hogenson TL; Fernandez-Zapico ME
    EMBO Mol Med; 2022 Apr; 14(4):e15707. PubMed ID: 35285156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impacting Pancreatic Cancer Therapy in Heterotypic
    Obaid G; Bano S; Mallidi S; Broekgaarden M; Kuriakose J; Silber Z; Bulin AL; Wang Y; Mai Z; Jin W; Simeone D; Hasan T
    Nano Lett; 2019 Nov; 19(11):7573-7587. PubMed ID: 31518145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
    Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
    Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalizing pancreatic cancer organoids with hPSCs.
    Zhang HC; Kuo CJ
    Nat Med; 2015 Nov; 21(11):1249-51. PubMed ID: 26540385
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 30.